Media Release
September 5, 2025

Idorsia to collaborate with two leading academic medical centers to launch IMPACT-HTN – a US initiative to transform care for patients with difficult-to-control hypertension

- Multi-phase program to standardize treatment, generate real-world evidence and explore AI-powered tools to improve outcomes for hypertension patients

Allschwil, Switzerland & Radnor, Philadelphia – September 5, 2025
Idorsia Ltd (SIX: IDIA) announces a first-of-its-kind initiative with the Stanford Hypertension Center and Duke Heart Center to launch IMPACT-HTN, a new three-phase program to transform and modernize the management of difficult-to-control hypertension. Patients requiring multiple medications for difficult-to-control hypertension face increasing challenges with care coordination, evaluation of underlying causes, and worsening outcomes. The initiative, led by Dr. Vivek Bhalla of the Stanford University School of Medicine and Dr. Sreekanth Vemulapalli of Duke University School of Medicine, is expected to generate real-world evidence, standardize clinical decision-making and deliver scalable tools that leverage AI technology to help identify patients with difficult-to-control hypertension who may benefit from innovative therapies that utilize new pathways, including Idorsia's once-daily TRYVIO™ (aprocitentan), the first systemic hypertension treatment to target a new pathway in over 30 years.

Sreekanth Vemulapalli, MD, Associate Professor of Medicine, Duke Heart Center, commented:
"With novel therapies emerging to improve hypertension control, we are thrilled to work with our esteemed colleagues at Stanford and other hypertension centers to standardize the evaluation, management and access to innovative therapies for our patients with difficult-to-control hypertension. We'll be collaborating with companies to develop high-touch AI tools aimed at supporting the care of our patients to meet people where they are. This is a cross-institutional collaboration which we hope to expand to improve the outcomes of our patients."

Despite progress in improving patient outcomes, hypertension remains a major global health issue, affecting an estimated 50% of adults in the U.S. Patients whose blood pressure that remains above target despite the use of appropriate therapy face significantly higher risks of cardiovascular events, including heart attack, stroke and kidney failure, and are nearly twice as likely to experience premature mortality compared to those with controlled blood pressure. Difficult-to-control hypertension is defined as above-goal elevated blood pressure in a patient despite the concurrent use of multiple antihypertensive drug classes.

Vivek Bhalla, MD, Associate Professor of Medicine/Nephrology, Founding Director of the Stanford Hypertension Center, commented:
"The IMPACT-HTN program challenges the boundaries of the standard care model for hypertension treatment by building a platform to fundamentally shift how we approach difficult-to-control hypertension. I'm proud to collaborate with Idorsia and Dr. Vemulapalli as well as Dr. Kenneth Mahaffey, the Founding Director of the Stanford Center for Clinical Research for this initiative. By developing and publishing best practices, analyzing real-world data and harnessing emerging technologies, we're working to deliver impactful solutions that can transform hypertension care and improve lives."

The multi-phased IMPACT-HTN program is expected to deliver actionable tools, data and insights to improve care for those with difficult-to-control hypertension, including:

- A digital care algorithm to standardize how difficult-to-control hypertension is assessed and managed. Through interactive tools such as patient-facing algorithms, AI chatbots and a program portal, this initiative aims to transform protocols to improve patient care.
- A personalized hypertension risk score that will build on existing risk scores for prevention to better identify difficult-to-control hypertension patients at risk for negative cardiovascular outcomes so appropriate treatment protocols can be implemented sooner.
- A prospective early patient experience initiative that will enroll patients from hypertension specialty centers to better understand the treatment obstacles for patients with difficult-to-control hypertension and how newer treatments, like Idorsia's TRYVIO, are impacting the treatment paradigm.

Srishti Gupta, MD, CEO of Idorsia, commented:
"We are proud to have pioneered the first treatment tackling a new pathway in hypertension in over three decades and as a leader in this area, we understand that our commitment to improving patient outcomes goes beyond the medicine. We are proud to collaborate with two of the world's leading research institutions, on this exciting new program and believe IMPACT-HTN will help reimagine the pathways of care for hypertension patients who need additional options."

TRYVIO, a dual endothelin receptor antagonist (ERA) is now available to prescribe. It is indicated for the treatment of hypertension in combination with other antihypertensive drugs to lower blood pressure (BP) in adult patients who are not adequately controlled on other drugs. TRYVIO is now included in the American College of Cardiology's (ACC) and the American Heart Association's (AHA) new comprehensive clinical practice guidelines for the management of high blood pressure, but many patients remain undiagnosed and undertreated.

Important Safety Information
TRYVIO may cause serious side effects, including:
TRYVIO can cause major birth defects if used by pregnant patients and has a BOXED Warning for embryo-fetal toxicity.

- **People who can become pregnant must not be pregnant when they start taking TRYVIO or become pregnant during treatment with TRYVIO or for 1 month after stopping treatment with TRYVIO.**
- **People who can become pregnant should have a negative pregnancy test** before starting treatment with TRYVIO, each month during treatment with TRYVIO, and 1 month after stopping TRYVIO.
- **People who can become pregnant should use acceptable birth control before starting treatment with TRYVIO, during treatment with TRYVIO, and for 1 month after stopping TRYVIO** because the medicine may still be in your body.

If you are a person who can become pregnant, your healthcare provider will talk to you about pregnancy testing recommendations and the need to use acceptable birth control, the benefits and risks of TRYVIO, and the need to report suspected pregnancy right away to your healthcare provider.

What is TRYVIO?
TRYVIO is a prescription medicine used to treat high blood pressure (hypertension) in adults who are taking other high blood pressure medicines and whose blood pressure is not well controlled.
Do not take TRYVIO if you are

- pregnant or currently trying to become pregnant.
- allergic to aprocitentan or any of the ingredients in TRYVIO.

Before taking TRYVIO, tell your healthcare provider about all of your medical conditions, including if you:

- have liver problems
- have heart failure
- have anemia
- have kidney problems or get dialysis
- are pregnant or plan to become pregnant during treatment with TRYVIO. TRYVIO can cause serious birth defects.
- are breastfeeding or plan to breastfeed. It is not known if TRYVIO passes into your breastmilk. **Do not breastfeed** if you take TRYVIO.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

TRYVIO may cause other serious side effects, including:

- Liver problems. TRYVIO may cause liver problems. Your healthcare provider should do blood tests to check your liver before starting treatment and as needed during treatment with TRYVIO. Tell your healthcare provider if you have any of the following symptoms of liver problems during treatment with TRYVIO:
  - **nausea or vomiting**
  - pain in the upper right stomach
  - tiredness
  - loss of appetite
  - **yellowing of your skin or whites of your eyes**
  - dark urine
  - fever
  - itching
- **Fluid retention.** Fluid retention and swelling are common during treatment with TRYVIO and can be serious. Tell your healthcare provider right away if you have any unusual weight gain, trouble breathing, or swelling of your ankles or legs. Your healthcare provider may treat you with other medicines (diuretics) if you develop fluid retention or swelling.
- **Low red blood cell levels (anemia).** Anemia is common during treatment with TRYVIO and can be serious. Your healthcare provider will do blood tests to check your red blood cells before starting and as needed during treatment with TRYVIO.
- **Decreased sperm count.** TRYVIO may cause decreased sperm counts in males and may affect the ability to father a child. Tell your healthcare provider if being able to have children is important to you.

Your healthcare provider may stop treatment with TRYVIO if you develop certain side effects. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of TRYVIO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

For more information see the Full Prescribing Information including BOXED Warning (PI and Medication Guide).

Notes to the editor

About aprocitentan

Aprocitentan is Idorsia's once-daily, orally active, dual endothelin receptor antagonist, which inhibits the binding of ET-1 to ETA and ETB receptors. Aprocitentan is approved as TRYVIO® in the US for the treatment of systemic hypertension in combination with other antihypertensives and has been commercially available since October 2024. Aprocitentan is approved as JERAYGO® for the treatment of resistant hypertension in combination with other antihypertensives in the European Union and the UK and marketing authorization applications are under review in Canada, and Switzerland.

About Idorsia

The purpose of Idorsia is to challenge accepted medical paradigms, answering the questions that matter most. To achieve this, we will discover, develop, and commercialize transformative medicines – either with in-house capabilities or together with partners – and evolve Idorsia into a leading biopharmaceutical company, with a strong scientific core.

Headquartered near Basel, Switzerland – a European biotech hub – Idorsia has a highly experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize the value of our portfolio; a promising in-house development pipeline; and a specialized drug discovery engine focused on small-molecule drugs that can change the treatment paradigm for many patients. Idorsia is listed on the SIX Swiss Exchange (ticker symbol: IDIA).

For further information, please contact:

Investor & Media Relations
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
investor.relations@idorsia.com – media.relations@idorsia.com – www.idorsia.com

The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as “intend”, "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs, business development activities and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.